Baveno VII – Renewing consensus in portal hypertension
By R. de Franchis, J. Bosch, G. Garcia‐Tsao, T. Reiberger, C. Ripoll, J. Abraldes, A. Albillos, A. Baiges, J. Bajaj, R. Bañares and 56 more. Journal of Hepatology, 2021
2,338 citations recorded by the source corpus.
Summary To expand on the work of previous meetings, a virtual Baveno VII workshop was organised for October 2021. Among patients with compensated cirrhosis or compensated advanced chronic liver disease (cACLD – defined at the Baveno VI conference), the presence or absence of clinically significant portal hypertension (CSPH) is associated with differing outcomes, including risk of death, and different diagnostic and therapeutic needs. Accordingly, the Baveno VII workshop was entitled “Personalized Care for Portal Hypertension”. The main fields of discussion were the relevance and indications for measuring the hepatic venous pressure gradient as a gold standard, the use of non-invasive tools for the diagnosis of cACLD and CSPH, the impact of aetiological and non-aetiological therapies on the course of cirrhosis, the prevention of the first episode of decompensation, the management of an acute bleeding episode, the prevention of further decompensation, as well as the diagnosis and management of splanchnic vein thrombosis and other vascular disorders of the liver. For each of these 9 topics, a thorough review of the medical literature was performed, and a series of consensus statements/recommendations were discussed and agreed upon. A summary of the most important conclusions/recommendations derived from the workshop is reported here. The statements are classified as unchanged, changed, and new in relation to Baveno VI.
Subfields: Epidemiology, Hepatology, Surgery
View Paper: https://www.semanticscholar.org/paper/3051ec7cef9266c60bf3e24aacb199a670e5accd
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- R. Rajaram
- W. Chan
- Lee-Ling Lim
- S. Vethakkan
- J. Ratnasingam
- Kee-Huat Chuah
Citations in the corpus
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review (2023, background): “92,97 Liver cirrhosis is a known risk factor for HCC. Surveillance with 6-monthly ultrasound examination of the liver with or without serum alpha-fetoprotein level is recommended by all major guidelines.”
- AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023, neutral): “[322] The optimal time to wait between band ligation and initiation of atezolizumab plus bevacizumab to minimize risk of bleeding from banding ulcers is unknown, although 2 weeks is likely reasonable given risk of post-banding ulcers.”